home / lobbying / lobbying_activities

lobbying_activities: 2817105

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2817105 ecea8bee-b66b-4e6a-aab7-dd9dadd5a31a Q2 HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 17966 EMERGENT BIOSOLUTIONS 2022 second_quarter DIS Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-07-12T12:36:48-04:00
Powered by Datasette · Queries took 104.777ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API